author-photo

Ajay K. Nooka

Emory University

307

Papers

5820

Citations

Citation Trend

Filter By

Papers (213) Sort By

Journal Conference Others

Recommendations on Eliminating Racial Disparities in Multiple Myeloma Therapies: A Step toward Achieving Equity in Healthcare

2021
Show All
- Source
- Cite
- Save
Citations (7)
Mitochondrial Electron Transport Chain Inhibition Promotes Resistance to Proteasome Inhibitors in Multiple Myeloma

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.

2021 Cancer
Show All
- Source
- Cite
- Save
Citations (3)
Poster: ABCL-378: Prolonged Cytopenias in Autologous Stem Cell Transplantation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.

2021 American Journal of Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
"I took the road less traveled, and that has made all the difference": Making a case for high-dose therapy and autologous stem cell transplantation in elderly patients with newly diagnosed multiple myeloma.

2021 Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Benefits of autologous stem cell transplant for elderly myeloma patients in the last quarter of life

2021
Show All
- Source
- Cite
- Save
Citations (0)
MM-078: Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM)

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy.

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (0)